ZARZA We are Zarza, the prestigious firm behind major projects in information technology.

Cyclic and Every-Other-Week Dosing of Intravenous Efgartigimod for Generalized Myasthenia Gravis Part A of ADAPT NXT

Perspectives on Selected Myasthenia Gravis Posters and Abstracts From AANEM

19/11/2024 3 min

Listen "Cyclic and Every-Other-Week Dosing of Intravenous Efgartigimod for Generalized Myasthenia Gravis Part A of ADAPT NXT"

Descargar episodio Ver en sitio original

Episode Synopsis

Author: Habib AA, et alOverview Provided by Nicolas Silvestri, MD

More episodes of the podcast Perspectives on Selected Myasthenia Gravis Posters and Abstracts From AANEM

Wrap Up 19/11/2024

Long-Term Safety and Efficacy of Zilucoplan in Generalized Myasthenia Gravis 120-Week Interim Analysis of RAISE-XT 19/11/2024

Efficacy and Safety of Nipocalimab in Patients with Generalized Myasthenia Gravis: Topline Results from the Double-Blind, Placebo-Controlled, Randomized Phase 3 VIVACITY-MG3 Study 19/11/2024

Concomitant Corticosteroid Use with Ravulizumab in Adults with Anti-Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: Phase 3 CHAMPION-MG Open-Label Extension Final Results 19/11/2024

Introduction 19/11/2024

Ver todos los episodios